上海爱科百发生物医药技术股份有限公司

CCOE

STARCOIN GROUP

ONEFORCE HLDGS

ROYAL DELUXE

STELUX HOLDINGS

TE HEALTHCARE

ASIAPAC FIN INV

WELIFE TECH

DRINDA

TIMELESS

<p>On February 11, 2026, Shanghai Ark Biopharmaceutical Co., Ltd. revealed that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AK3280. This drug is a new anti-fibrotic treatment aimed at treating idiopathic conditions. This development signifies a significant step forward in the company's efforts to introduce innovative therapies into the market.</p>

Unusual Whales

FDA clears IND application for novel anti-fibrotic drug AK3280 by ArkBio, leading to Phase 2 clinical trial for IPF.

<p>Shanghai Ark Biopharmaceutical Co., Ltd. announced that the FDA has cleared its IND application for AK3280, a novel anti-fibrotic drug for idiopathic pulmonary fibrosis (IPF). This allows ArkBio to start a Phase 2 proof-of-concept clinical trial in the U.S. The trial aims to evaluate the efficacy, safety, and pharmacokinetics of AK3280, which has shown promising results in previous studies. The FDA clearance is a significant milestone for ArkBio in developing better treatment options for IPF patients.</p>

prnewswire

23:18 ETNovel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

上海爱科百发生物医药技术股份有限公司(N21149.HK)

FDA clears IND application for novel anti-fibrotic drug AK3280 by ArkBio, leading to Phase 2 clinical trial for IPF.

23:18 ETNovel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF